Aeterna Zentaris Presents Proof-of-Concept for Disorazol Z Cytotoxic Conjugates, such as AEZS-125, in Ovarian Cancer Mouse Model at ENA Symposium

About this update from Cosciens Biopharma Inc.

[{"type":"text","content":"\n\n\n\n\n\nQUÉBEC CITY, CANADA, Nov. 8, 2012 /CNW Telbec/ - Aeterna Zentaris Inc.\n (NASDAQ: AEZS) (TSX: AEZ) (the \"Company\") today presented encouraging\n preclinical results for disorazol Z cytotoxic conjugates, such as\n AEZS-125, in ovarian cancer. Results showed the compound's high\n potential for the treatment of luteinizing hormone-releasing hormone\n (LHRH) receptor positive tumors. Data were presented by the Company's\n Director of Preclinical Development, Babette Aicher, PhD, during a\n poster presentation at the 24th EORTC-NCI-AACR (ENA) Symposium on \"Molecular Targets and Cancer\n Therapeutics\", currently held in Dublin, Ireland. The study is funded\n through a grant from the German Ministry of Education and Research.\n\n\nJuergen Engel, PhD, Aeterna Zentaris President and CEO stated,\n \"Disorazol Z cytotoxic conjugates such as AEZS-125, are an extension of\n our AEZS-108 innovative LHRH receptor targeted platform in oncology.\n These encouraging results presented at the ENA Symposium will enable us\n to select a specific drug candidate for further preclinical development\n expected to start in the first quarter of 2013.\"\n\n\nConclusions\n\n\nAll conjugates of D-Lys6 -LHRH and disorazol Z analyzed, demonstrated high potential\nregarding the treatment of LHRH-receptor positive tumors;\n\n\nFor all conjugates, including AEZS-125, proof-of-concept could be\n demonstrated in an\nLHRH-receptor positive A2780 ovarian cancer xenograft model;\n\n\nExperiments are currently under way addressing:\n\n\nCorrelation of tumor LHRH-receptor expression and treatment efficacy;\n\n\nEvaluation of additional tumor models, such as endometrium and\n triple-negative breast cancer;\n\n\nAssessment of early safety parameters and orientating acute toxicity in\n rodent models.\n\nThe poster, \"Highly Potent Cytotoxic Conjugates of Disorazol Z Linked to a\n LHRH-Receptor Targeting Peptide such as AEZS-125, Interfere with Cell\n Cycle Progression in Human Cancer Cell Lines and Suppress Tumor Growth\n in a LHRH-Receptor Positive Ovarian Cancer Xenograft Model\", B. Aicher, T. Schuster, L. Blumenstein, P. Schmidt, H. Irschik, R.\n Jansen, R. Mueller, E. Guenther, M. Teifel, can be viewed through this link.\n\n\nAbout Disorazol Z Cytotoxic Conjugates such as AEZS-125 \n\n\nAEZS-125 is a disorazol Z (AEZS-137) cytotoxic ...

More updates from Cosciens Biopharma Inc.